The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers

被引:79
作者
Rothman, N
Bhatnagar, VK
Hayes, RB
Zenser, TV
Kashyap, SK
Butler, MA
Bell, DA
Lakshmi, V
Jaeger, M
Kashyap, R
Hirvonen, A
Schulte, PA
Dosemeci, M
Hsu, F
Parikh, DJ
Davis, BB
Talaska, G
机构
[1] NATL INST OCCUPAT HLTH,AHMEDABAD,GUJARAT,INDIA
[2] VET AFFAIRS MED CTR,ST LOUIS,MO 63125
[3] ST LOUIS UNIV,SCH MED,ST LOUIS,MO 63125
[4] NIOSH,CINCINNATI,OH 45267
[5] NIEHS,RES TRIANGLE PK,NC 27709
[6] UNIV CINCINNATI,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267
关键词
D O I
10.1073/pnas.93.10.5084
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Several epidemiologic studies indicate that NAT2-related slow N-acetylation increases bladder cancer risk among workers exposed to aromatic amines, presumably because N-acetylation is important for the detoxification of these compounds. Previously, we showed that NAT2 polymorphisms did not influence bladder cancer risk among Chinese workers exposed exclusively to benzidine (BZ), suggesting that NAT2 N-acetylation is not a critical detoxifying pathway for this aromatic amine. To evaluate the biologic plausibility of this finding, we carried out a cross-sectional study of 33 workers exposed to BZ and 15 unexposed controls in Ahmedabad, India, to evaluate the presence of BZ-related DNA adducts in exfoliated urothelial cells, the excretion pattern of BZ metabolites, and the impact of NAT2 activity on these outcomes. Four DNA adducts were significantly elevated in exposed workers compared to controls; of these, the predominant adduct cochromatographed with a synthetic N-(3'phosphodeoxyguanosin-8-yl)-N'-acetylbenzidine standard and was the only adduct that was significantly associated with total BZ urinary metabolites (r = 0.68, P < 0.0001). To our knowledge this is the first report to show that BZ forms DNA adducts in exfoliated urothelial cells of exposed humans and that the predominant adduct formed is N-acetylated, supporting the concept that monofunctional acetylation is an activation, rather than a detoxification, step for BZ. However, because almost all BZ-related metabolites measured in the urine of exposed workers were acetylated among slow, as well as rapid, acetylators (mean +/- SD 95 +/- 1.9% vs. 97 +/- 1.6%, respectively) and NAT2 activity did not affect the levels of any DNA adduct measured, it is unlikely that interindividual variation in NAT2 function is relevant for BZ-associated bladder carcinogenesis.
引用
收藏
页码:5084 / 5089
页数:6
相关论文
共 50 条
[1]  
BADAWI AF, 1995, CANCER RES, V55, P5230
[2]  
BELL DA, 1995, CANCER RES, V55, P3537
[3]  
BELL DA, 1995, CANCER RES, V55, P5226
[4]   GENOTYPE-PHENOTYPE DISCORDANCE FOR HUMAN ARYLAMINE N-ACETYLTRANSFERASE (NAT2) REVEALS A NEW SLOW-ACETYLATOR ALLELE COMMON IN AFRICAN-AMERICANS [J].
BELL, DA ;
TAYLOR, JA ;
BUTLER, MA ;
STEPHENS, EA ;
WIEST, J ;
BRUBAKER, LH ;
KADLUBAR, FF ;
LUCIER, GW .
CARCINOGENESIS, 1993, 14 (08) :1689-1692
[5]   MORTALITY AND INCIDENCE OF BLADDER-CANCER IN BENZIDINE-EXPOSED WORKERS IN CHINA [J].
BI, WF ;
HAYES, RB ;
FENG, PW ;
QI, YY ;
YOU, XJ ;
ZHEN, JG ;
ZHANG, MQ ;
QU, BQ ;
FU, ZY ;
CHEN, M ;
CHIEN, HTC ;
BLOT, WJ .
AMERICAN JOURNAL OF INDUSTRIAL MEDICINE, 1992, 21 (04) :481-489
[6]   MOLECULAR MECHANISM OF SLOW ACETYLATION OF DRUGS AND CARCINOGENS IN HUMANS [J].
BLUM, M ;
DEMIERRE, A ;
GRANT, DM ;
HEIM, M ;
MEYER, UA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) :5237-5241
[7]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[8]  
CARTWRIGHT RA, 1982, LANCET, V2, P842
[9]   BENZIDINE AND ITS ACETYLATED METABOLITES IN THE URINE OF WORKERS EXPOSED TO DIRECT BLACK 38 [J].
DEWAN, A ;
JANI, JP ;
PATEL, JS ;
GANDHI, DN ;
VARIYA, MR ;
GHODASARA, NB .
ARCHIVES OF ENVIRONMENTAL HEALTH, 1988, 43 (04) :269-272
[10]  
FLAMMANG TJ, 1989, CANCER RES, V49, P1977